Amrutanjan Health Care Ltd (AMRUTANJAN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Amrutanjan Health Care Ltd on NSE and BSE, with an AI summary of each filing.
Investor Presentation for the Quarter Ended 30th September 2026
Investor Presentation · 04 Nov 2026, 5:16 am
Amrutanjan Health Care Q2 FY27 Financial Results and Operational Update Amrutanjan Health Care delivered strong Q2 FY27 performance, with net sales rising 14.85% YoY to Rs. 135.18 Cr and PAT increasing 23.78% YoY to Rs. 17.28 Cr. Growth was driven by Women’s Hygiene & Personal Care (up 23.49% YoY to Rs. 40.48 Cr) and OTC sales (up 13.65% YoY to Rs. 90.94 Cr). Operating margins expanded 200 bps QoQ despite rising raw material costs. For FY27, management guides 12-15% revenue growth and aims to sustain a 12% operating profit margin.
Record Date for the first interim dividend 2026-27
Dividend · 03 Nov 2026, 11:57 pm
Amrutanjan Health Care Fixes Record Date for FY27 First Interim Dividend Amrutanjan Health Care Limited has fixed 7th Nov'26 as the record date pursuant to Regulation 42 of SEBI LODR Regulations. The date will determine eligible equity shareholders and beneficial owners across NSDL and CDSL depositories for the payment of the company's 1st Interim Dividend for FY27.
Outcome for the Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026
Outcome · 03 Nov 2026, 11:47 pm
Amrutanjan Health Care Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Re. 1 per equity share.
Outcome · 03 Nov 2026, 11:44 pm
Amrutanjan Health Care Q2 FY27 Results: PAT Rises 23.8% YoY, Declares Interim Dividend Amrutanjan Health Care reported a 14.85% YoY increase in revenue from operations to INR 13,517.89 lakhs for Q2 ended 30th Sep'26. Profit after tax rose 23.77% YoY to INR 1,727.99 lakhs, with basic and diluted EPS reaching INR 5.98 versus INR 4.83 in Q2 FY26. For H1 ended 30th Sep'26, revenue stood at INR 23,814.77 lakhs with PAT of INR 2,164.56 lakhs. The board declared a first interim dividend of Re. 1 per equity share (aggregating to INR 289.11 lakhs) for FY27.
Amrutanjan Health Care Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 03 Nov 2026, 11:42 pm
Amrutanjan Health Care Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs) ■ Revenue: 13,518 (+14.9% YoY | +31.3% QoQ) ■ EBITDA: 2,361 (+42.9% YoY | +278.3% QoQ) ■ EBITDA Margin (%): 17.5 (+343 bps YoY | +1141 bps QoQ) ■ PAT: 1,728 (+23.8% YoY | +295.8% QoQ) ■ EPS (INR): 5.98 (+23.8% YoY | +296.0% QoQ) Amrutanjan Health Care Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs) Segmental Performance OTC Products ■ Revenue: 9,094 (+13.6% YoY | +58.8% QoQ) ■ EBIT: 2,329 (+26.5% YoY | +135.9% QoQ) ■ EBIT Margin (%): 25.6 (+260 bps YoY | +836 bps QoQ) Women's Hygiene & Personal Care ■ Revenue: 4,048 (+23.5% YoY | +11.3% QoQ) ■ EBIT: 46.2 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 1.1 (Loss to Profit YoY | Loss to Profit QoQ) Beverages ■ Revenue: 303 (-29.4% YoY | -65.0% QoQ) ■ EBIT: -241 (-271.9% YoY | -91.5% QoQ) ■ EBIT Margin (%): -79.7 (-6458 bps YoY | -6512 bps QoQ) Others ■ Revenue: 73.2 (+19.5% YoY | +2.2% QoQ) ■ EBIT: 14.2 (Loss to Profit YoY | +318.0% QoQ) ■ EBIT Margin (%): 19.3 (Loss to Profit YoY | +1462 bps QoQ)
AMRUTANJAN HEALTH CARE LIMITED has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Dividend.
Intimation · 03 Nov 2026, 5:30 am
Amrutanjan Health Care Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Unaudited Financial ....
Intimation · 03 Nov 2026, 5:30 am
Amrutanjan Health Care Board to Consider Q2 Results and Interim Dividend Amrutanjan Health Care Ltd announced that its Board of Directors will meet on 3rd Nov'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. The board will also evaluate the declaration of a 1st interim dividend for FY26-27. Additionally, the company's trading window for dealing in equity shares remains closed from 1st Oct'26 until 5th Nov'26 in compliance with SEBI insider trading regulations.
To consider and approve the financial results for the period ended September 30, 2026 and dividend
Intimation · 03 Nov 2026, 5:30 am
Intimation of ESG Ratings
Others (Uncategorized) · 09 Oct 2026, 5:11 pm
Amrutanjan Health Care Receives Voluntary CRISIL ESG Rating of 60 CRISIL ESG Ratings & Analytics Limited has voluntarily assigned an ESG score of 60 to Amrutanjan Health Care Limited, placing the company in the "Adequate" category. The rating agency conducted this assessment independently using publicly available disclosures and public domain ESG parameters, as the company had not engaged CRISIL for an ESG rating service.
Voting Results and Scrutinizer Report of 89th Annual General Meeting
Annual General Meeting · 24 Sept 2026, 9:19 pm
Proceedings of 89th Annual General Meeting
Annual General Meeting · 23 Sept 2026, 10:42 pm
BRSR Report for the financial year ended March 31, 2026.
Others (Uncategorized) · 28 Aug 2026, 7:21 pm
Annual Report of 89th Annual General Meeting to be held on 23rd September 2026
Others (Uncategorized) · 28 Aug 2026, 7:16 pm
Investor Presentation for the Quarter Ended 30th June 2026
Investor Presentation · 13 Aug 2026, 2:09 am
Amrutanjan Q1FY27: Women's Hygiene Leads Growth, Pain Management Declines Amrutanjan's Q1FY27 net sales grew 9.5% YoY to ₹103.0 Cr, but PBT fell to ₹6.1 Cr from ₹11.3 Cr due to a ₹2.0 Cr exceptional item and higher expenses. The Women's Hygiene (Comfy) segment was the key driver, with sales surging 27.1% YoY, contributing 33% to total revenue. In contrast, the dominant Pain Management segment declined 9% amid market-wide softness. Beverages grew 11.3%. New launches, including razors and plasters, contributed 4% to sales. Management expects double-digit revenue and profit growth for the full year.
Record Date for the Final Dividend and AGM
Dividend · 12 Aug 2026, 12:04 am
Financial Results and Outcome of the Board Meeting
Outcome · 11 Aug 2026, 11:54 pm
Amrutanjan Board Approves Q1FY27 Results and Final Dividend Record Date Amrutanjan Health Care reported Q1FY27 results on 11 Aug'26, with revenue at ₹10,296.88 lakhs (+9.5% YoY) and PAT at ₹436.57 lakhs (-47.5% YoY). The profit decline was primarily driven by an exceptional item of ₹202.75 lakhs related to a lease rent settlement. The Board scheduled the 89th AGM for 23 Sep'26 and set the record date for the final dividend at 11 Sep'26. Basic EPS for the quarter stood at ₹1.51, down from ₹2.87 in Q1FY26.
Additional Details Required for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 06 Aug 2026, 11:57 pm
Amrutanjan Explains Delay in Credit Rating Disclosure to BSE Amrutanjan Health Care responded to the BSE on 6 Aug'26 regarding a delayed intimation for a credit rating received on 5 Aug'26. The company cited the unexpected unavailability of Key Managerial Personnel (KMP) due to sudden travel, which prevented timely authorization. Amrutanjan confirmed no price-sensitive information was revealed as the trading window was closed for designated persons. It requested the exchange to condone the inadvertent delay, assuring future timely compliance and upholding high governance standards.
Commissioning of New Manufacturing Facility
Others (Uncategorized) · 05 Aug 2026, 6:20 pm
Amrutanjan Commissions ₹150cr Greenfield Sanitary Napkin Plant in Telangana Amrutanjan Health Care commissioned its fifth manufacturing plant, a greenfield facility in Telangana, on 5 Aug'26 with a ₹150 crore investment. The plant, focused on producing sanitary napkins for its Comfy brand, has a planned annual capacity of 700 million units. Located on a 10-acre site, it features two high-speed automated production lines from Japan. This strategic expansion aims to meet growing demand for feminine hygiene products, strengthen its "Make in India" initiative, and enhance its leadership in the sector.
Announcement under Regulation 30 (LODR)- Credit Rating
Others (Uncategorized) · 05 Aug 2026, 5:51 pm
Amrutanjan Health Care Assigned 'CARE A; Stable' Issuer Rating CARE Ratings assigned Amrutanjan Health Care a 'CARE A; Stable' issuer rating on 05 Aug'26. The rating reflects its strong brand recall, debt-free capital structure, comfortable liquidity with a ₹221.85 cr cash balance, and healthy operating margins of 15.06% in FY26. Total operating income grew 11% YoY to ₹502.55 cr. However, the rating is constrained by modest scale, product concentration in pain relief (~60% of revenue), and intense FMCG competition. Key sensitivities include operating income declining below ₹400 cr or significant debt-funded capex.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DSP Trustee Pvt Ltd & Others
Acquisition/ Disposal of Shares · 05 Aug 2026, 4:06 pm
DSP Mutual Fund reduces stake in Amrutanjan Health Care below 3% DSP Trustee Private Limited, on behalf of DSP Mutual Fund schemes, sold 2,11,361 shares of Amrutanjan Health Care via an open market transaction on 31st Jul'26. This sale has reduced DSP's total holding in the company from 3.55% (10,27,581 shares) to 2.82% (8,16,220 shares). The disposal represents a 0.73% stake reduction, triggering a disclosure under SEBI's Takeover Regulations due to a change in shareholding exceeding 2% from the last report filed on 06th Feb'23, when the holding crossed 5%.
Intimation of under Regulation 30 read with Clause 20 of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 02 Aug 2026, 1:14 am
Amrutanjan Pays ₹9.75 Crore Lease Arrears After High Court Order Amrutanjan Health Care paid ₹9.75 crore in lease rent arrears on 1 Aug '26 to Kapaleeswarar Temple, complying with a Madras High Court order. The payment follows the dismissal of the company's writ petition which challenged a provision of the Tamil Nadu Hindu Religious and Charitable Endowment Act. The High Court's order was dated 17 Mar '26, with payment due by 2 Aug '26. The company stated there is no significant impact on its business and operations from this event.
Reconstitution Of Committees of Board of Directors
Others (Uncategorized) · 27 May 2026, 11:39 pm
Amrutanjan Announces Key Board Committee Leadership Changes Following Mr. Raja Venkataraman's cessation as Director, Amrutanjan Health Care has reconstituted its board committees effective 26th May'26. Mr. Ramaswami Krishnan has been appointed as the new Chairman of the Audit Committee. Additionally, Mr. Krishnan will serve as a Member of both the Corporate Social Responsibility Committee and the Risk Management Committee, assuming all positions previously held by Mr. Venkataraman. This change ensures continuity in key governance and oversight functions for the company.
Completion of tenure of Mr. Raja Venkataraman as an Independent Director.
Change in Management · 27 May 2026, 3:02 am
Amrutanjan Board Change: Independent Director Completes Term Mr. Raja Venkataraman (DIN: 00669376) has ceased to be an Independent Director of Amrutanjan Health Care Limited effective 26 May'26. This change in board composition is due to the completion of his first term. The company confirmed there are no other material disclosures or relationships to report concerning this cessation.
Financial Results - Machine Readable Format
Others (Uncategorized) · 13 May 2026, 5:34 pm
Amrutanjan FY26 Results: Recommends Rs. 2.90 Dividend and Board Changes Amrutanjan Health Care's Board approved FY26 results on 8 May'26, recommending a final dividend of Rs. 2.90 per share. FY26 PAT rose 13.9% YoY to Rs. 5,791.78 lakhs, with revenue up 11.2% YoY to Rs. 50,255.27 lakhs. For Q4FY26, PAT stood at Rs. 1,619.28 lakhs, down 16.8% QoQ, on revenue of Rs. 14,976.81 lakhs. The board also approved appointments for Mr. Ramaswami Krishnan and Mr. Muralidharan Swayambunathan as Non-Executive Independent Directors, along with a revised ESOP scheme.
Investor Presentation for the Quarter and year ended 31st March 2026
Investor Presentation · 09 May 2026, 8:42 pm
Amrutanjan FY26 Results: Strong Growth Driven by Core Brands and Margin Expansion Amrutanjan Health Care reported robust FY26 results with net sales growing 11.2% YoY to ₹502.55 Cr and PAT increasing 14.0% to ₹57.92 Cr. Growth was driven by the Pain Management (+10%) and Women's Hygiene (+19%) segments. For Q4 FY26, net sales rose 10.6% YoY to ₹149.77 Cr, while profit before exceptional items grew 37.2% to ₹28.62 Cr. Management guides for continued demand, a new sanitary pad plant in May to improve Comfy's profitability, and expects to mitigate COGS inflation via price increases.